Hassoun Lauren A, Sivamani Raja K, Sharon Victoria R, Silverstein Marc A, Burrall Barbara A, Tartar Danielle M
Department of Dermatology, University of California Davis School of Medicine, Sacramento, California.
Dermatol Online J. 2017 Jul 15;23(7):13030/qt3k32k916.
We present a 42-year-old woman with no history of diabetes or glucose intolerance who had a 5-year history of ulcerative necrobiosis lipoidica (NL). Despite failure of multiple medications, she experienced clearing of her ulcers after her treatment was changed to ustekinumab. We discuss our patient's disease course and elaborate upon mechanistic reasons for her improvement related to ustekinumab therapy.
我们报告了一名42岁女性，她既往无糖尿病或糖耐量异常病史，患有溃疡性类脂质渐进性坏死（NL）5年。尽管多种药物治疗均失败，但在将治疗改为优特克单抗后，她的溃疡得以愈合。我们讨论了该患者的病程，并详细阐述了与优特克单抗治疗相关的病情改善的机制性原因。
